LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. SPY
2. AKAM
3. COST
4. META
5. NVDA
6. ZS
7. OKTA
8. VEON
9. PRME
10. AWK

Go back to LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Merck & Co. (NYSE: MRK) Delayed: 148.78 --0 (-0%)
Previous Close $148.78    52 Week High $65.46 
Open $148.78    52 Week Low $47.97 
Day High $148.78    P/E 101.21 
Day Low $148.78    EPS $1.47 
Volume 2,585